CoChat
Sign Up
Cited by 43

The DOI matches its Crossref record.

Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity

Tripathi, Devika, Pandey, Prashant, Sharma, Sakshi, Rai, Awani K, Prabhu B.H., Manjunatha·2024·BioImpacts
DOI 10.34172/bi.30573PMC PMC12008503
Open this paper in CoChat — free account

Abstract

By integrating the cutting-edge principles of nanotechnology with medical science, nanomedicine offers unprecedented opportunities to develop advanced drug delivery systems that surpass the limitations of conventional therapies. These nanoscale systems are designed to enhance treatments' efficacy, specificity, and safety by optimizing pharmacokinetics and biodistribution, ensuring that therapeutic agents reach their intended targets with minimal side effects. The article provides an in-depth analysis of nanomaterials' pivotal role in overcoming challenges related to drug delivery, including the ability to bypass biological barriers, improve bioavailability, and achieve controlled release of drugs. Despite these promising advancements, the transition of nanomedicine from research to clinical practice faces significant hurdles. The review highlights key obstacles such as patient heterogeneity, physiological variability, and the complex ADME (Absorption, Distribution, Metabolism, Excretion) profiles of nanocarriers, which complicate treatment predictability and effectiveness. Moreover, the article addresses the issues of limited tissue penetration, variable patient responses, and the need for standardized protocols in nanomaterial characterization, all of which hinder the widespread clinical adoption of nanomedicine. Nevertheless, the potential of nanomedicine in revolutionizing personalized cancer therapy remains immense. The article advocates for increased translational research and international collaboration to overcome these challenges, paving the way for fully realizing nanomedicine's capabilities in precision oncology and beyond.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.34172/bi.30573

Cites

Statistics

Figures

Fig. 1
Fig. 1 CC BY-NC · PubMed Central
Fig. 2
Fig. 2 CC BY-NC · PubMed Central
Fig. 3
Fig. 3 CC BY-NC · PubMed Central
Fig. 4
Fig. 4 CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 208

  1. [1]Sengupta A, Sarkar CK. Introduction to Nano: Basics to Nanoscience and Nanotechnology. Springer; 2015. 10.1007/978-3-662-47314-6. · DOI
  2. [2]Mansoori GA. an introduction to nanoscience and nanotechnology. In: Ghorbanpour M, Manika K, Varma A, eds. Nanoscience and Plant–Soil Systems. Cham: Springer; 2017. p. 3-20. 10.1007/978-3-319-46835-8_1. · DOI
  3. [3]Collins BX Wilkins CH Overcoming barriers to health equity in precision medicine research Am J Bioeth 2024 24 86 8 10.1080/15265161.2024.2303146 38394005 · DOI
  4. [4]Stenzinger A Moltzen EK Winkler E Molnar-Gabor F Malek N Costescu A Implementation of precision medicine in healthcare-a European perspective J Intern Med 2023 294 437 54 10.1111/joim.13698 37455247 · DOI
  5. [5]Joo JI Choi M Jang SH Choi S Park SM Shin D Realizing cancer precision medicine by integrating systems biology and nanomaterial engineering Adv Mater 2020 32 e1906783 10.1002/adma.201906783 32253807 · DOI
  6. [6]Pandey P Kumar Arya D Kumar Ramar M Chidambaram K Rajinikanth PS Engineered nanomaterials as an effective tool for HER2 + breast cancer therapy Drug Discov Today 2022 27 2526 40 10.1016/j.drudis.2022.06.007 35753642 · DOI
  7. [7]Svensson E von Mentzer U Stubelius A Achieving precision healthcare through nanomedicine and enhanced model systems ACS Mater Au 2024 4 162 73 10.1021/acsmaterialsau.3c00073 38496040 PMC10941278 · DOI
  8. [8]Nikandish M Wang H Bao X Nikandish M Enhancing drug delivery precision: development and optimization of nanoparticle-based formulations for targeted therapy in preclinical models Eur Sci J 2024 26 232 44 10.19044/esipreprint.2.2024.p232 · DOI
  9. [9]Mitchell MJ Billingsley MM Haley RM Wechsler ME Peppas NA Langer R Engineering precision nanoparticles for drug delivery Nat Rev Drug Discov 2021 20 101 24 10.1038/s41573-020-0090-8 33277608 PMC7717100 · DOI · Paper page
  10. [10]Watchorn J Clasky AJ Prakash G Johnston IAE Chen PZ Gu FX Untangling mucosal drug delivery: engineering, designing, and testing nanoparticles to overcome the mucus barrier ACS Biomater Sci Eng 2022 8 1396 426 10.1021/acsbiomaterials.2c00047 35294187 · DOI
  11. [11]Đorđević S Gonzalez MM Conejos-Sánchez I Carreira B Pozzi S Acúrcio RC Current hurdles to the translation of nanomedicines from bench to the clinic Drug Deliv Transl Res 2022 12 500 25 10.1007/s13346-021-01024-2 34302274 PMC8300981 · DOI
  12. [12]Kobayashi H Watanabe R Choyke PL Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 2013 4 81 9 10.7150/thno.7193 24396516 PMC3881228 · DOI · Paper page
  13. [13]Zi Y Yang K He J Wu Z Liu J Zhang W Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms Adv Drug Deliv Rev 2022 188 114449 10.1016/j.addr.2022.114449 35835353 · DOI · Paper page
  14. [14]Samuel HS Ekpan FM Revolutionizing drugs administration: techniques in drug delivery and development Int J Biochem Physiol 2023 8 000237 10.23880/ijbp-16000238 · DOI
  15. [15]Li H Luo Q Zhang H Ma X Gu Z Gong Q Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation Chem Soc Rev 2023 52 47 96 10.1039/d2cs00437b 36427082 · DOI
  16. [16]Sufian MA Ilies MA Lipid-based nucleic acid therapeutics with in vivo efficacy Wiley Interdiscip Rev Nanomed Nanobiotechnol 2023 15 e1856 10.1002/wnan.1856 36180107 PMC10023279 · DOI
  17. [17]Leal AD Krishnamurthy A Head L Messersmith WA Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer Expert Opin Investig Drugs 2018 27 901 16 10.1080/13543784.2018.1541085 30359534 · DOI
  18. [18]Tong JT Harris PW Brimble MA Kavianinia I An insight into FDA approved antibody-drug conjugates for cancer therapy Molecules 2021 26 5847 10.3390/molecules26195847 34641391 PMC8510272 · DOI
  19. [19]Fingrut W Davis W McGinnis E Dallas K Ramadan K Merkeley H Reevaluating patient eligibility for inotuzumab ozogamicin based on CD22 expression: is dim expression sufficient? Curr Oncol 2020 28 252 9 10.3390/curroncol28010027 33704192 PMC7900888 · DOI
  20. [20]Munster P Krop IE LoRusso P Ma C Siegel BA Shields AF Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study Br J Cancer 2018 119 1086 93 10.1038/s41416-018-0235-2 30361524 PMC6219487 · DOI
  21. [21]Tripathi D Srivastava M Rathour K Rai AK Wal P Sahoo J A promising approach of dermal targeting of antipsoriatic drugs via engineered nanocarriers drug delivery systems for tackling psoriasis Drug Metab Bioanal Lett 2023 16 89 104 10.2174/2949681016666230803150329 37534794 · DOI
  22. [22]Hersh AM Alomari S Tyler BM Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology Int J Mol Sci 2022 23 4153 10.3390/ijms23084153 35456971 PMC9032478 · DOI · Paper page
  23. [23]Human SH 774 Phase Ib trial of escalating doses of SGT-53 infusion in combination with docetaxel in advanced solid tumor patients Mol Ther 2014 22 S299 10.1016/s1525-0016(16)35787-2 · DOI
  24. [24]Pedrosa PM. Gold Nanoparticles to Tackle Drug Resistance in Cancer [dissertation]. Portugal: Universidade NOVA de Lisboa; 2019.
  25. [25]Natarajan JV Nugraha C Ng XW Venkatraman S Sustained-release from nanocarriers: a review J Control Release 2014 193 122 38 10.1016/j.jconrel.2014.05.029 24862321 · DOI
  26. [26]Park JW Liposome-based drug delivery in breast cancer treatment Breast Cancer Res 2002 4 95 9 10.1186/bcr432 12052251 PMC138729 · DOI
  27. [27]Desai N. Nanoparticle albumin-bound paclitaxel (Abraxane®). In: Otagiri M, Chuang VT, eds. Albumin in Medicine: Pathological and Clinical Applications. Singapore: Springer; 2016. p. 101-19. 10.1007/978-981-10-2116-9_6. · DOI
  28. [28]Wang Q Atluri K Tiwari AK Babu RJ Exploring the application of micellar drug delivery systems in cancer nanomedicine Pharmaceuticals (Basel) 2023 16 433 10.3390/ph16030433 36986532 PMC10052155 · DOI
  29. [29]Petersen GH Alzghari SK Chee W Sankari SS La-Beck NM Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin J Control Release 2016 232 255 64 10.1016/j.jconrel.2016.04.028 27108612 · DOI
  30. [30]Giménez E Bustelos R De la Serna J Grande C Intrathecal liposomal cytarabine (DepoCyte®) as treatment for CNS infiltration in an adult woman with acute myeloid leukaemia Bone Marrow Transplant 2005 35 S378 92 10.1038/sj.bmt.1704924 · DOI
  31. [31]Modi D Hussain MS Ainampudi S Prajapati BG Long acting injectables for the treatment of prostate cancer J Drug Deliv Sci Technol 2024 100 105996 10.1016/j.jddst.2024.105996 · DOI
  32. [32]Mohan A Narayanan S Balasubramanian G Sethuraman S Krishnan UM Dual drug loaded nanoliposomal chemotherapy: a promising strategy for treatment of head and neck squamous cell carcinoma Eur J Pharm Biopharm 2016 99 73 83 10.1016/j.ejpb.2015.11.017 26690333 · DOI
  33. [33]Zhang R Kiessling F Lammers T Pallares RM Clinical translation of gold nanoparticles Drug Deliv Transl Res 2023 13 378 85 10.1007/s13346-022-01232-4 36045273 PMC9432795 · DOI
  34. [34]Aldhafeeri MM. The Interaction of Nanoparticles with Mucosal Barriers [dissertation]. Newcastle University; 2019.
  35. [35]Von Hoff DD Mita MM Ramanathan RK Weiss GJ Mita AC LoRusso PM Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors Clin Cancer Res 2016 22 3157 63 10.1158/1078-0432.ccr-15-2548 26847057 · DOI
  36. [36]Gaillard PJ Appeldoorn CC Dorland R van Kregten J Manca F Vugts DJ Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101) PLoS One 2014 9 e82331 10.1371/journal.pone.0082331 24416140 PMC3885379 · DOI
  37. [37]Pillai G. Nanotechnology toward treating cancer: a comprehensive review. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas S, eds. Applications of Targeted Nano Drugs and Delivery Systems. Elsevier; 2019. p. 221-56. 10.1016/b978-0-12-814029-1.00009-0. · DOI
  38. [38]Duncan R Gaspar R Nanomedicine(s) under the microscope Mol Pharm 2011 8 2101 41 10.1021/mp200394t 21974749 · DOI
  39. [39]El-Sherbiny IM El-Baz NM Yacoub MH Inhaled nano- and microparticles for drug delivery Glob Cardiol Sci Pract 2015 2015 2 10.5339/gcsp.2015.2 26779496 PMC4386009 · DOI
  40. [40]Ruela AL Perissinato AG de Sousa Lino ME Mudrik PS Pereira GR Evaluation of skin absorption of drugs from topical and transdermal formulations Braz J Pharm Sci 2016 52 527 44 10.1590/s1984-82502016000300018 · DOI
  41. [41]Singh V Srivastava D Pandey P Kumar M Yadav S Kumar D Characterization, antibacterial and anticancer study of silk fibroin hydrogel J Drug Deliv Ther 2023 13 21 31 10.22270/jddt.v13i2.5733 · DOI
  42. [42]Kapoor A Mishra SK Verma DK Pandey P Chemical penetration enhancers for transdermal drug delivery system J Drug Deliv Ther 2018 8 62 6 10.22270/jddt.v8i5-s.1952 · DOI
  43. [43]Ajdary M Moosavi MA Rahmati M Falahati M Mahboubi M Mandegary A Health concerns of various nanoparticles: a review of their in vitro and in vivo toxicity Nanomaterials (Basel) 2018 8 634 10.3390/nano8090634 30134524 PMC6164883 · DOI
  44. [44]Chenthamara D Subramaniam S Ramakrishnan SG Krishnaswamy S Essa MM Lin FH Therapeutic efficacy of nanoparticles and routes of administration Biomater Res 2019 23 20 10.1186/s40824-019-0166-x 31832232 PMC6869321 · DOI
  45. [45]Hoshyar N Gray S Han H Bao G The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction Nanomedicine (Lond) 2016 11 673 92 10.2217/nnm.16.5 27003448 PMC5561790 · DOI · Paper page
  46. [46]Wang Y Pi C Feng X Hou Y Zhao L Wei Y The influence of nanoparticle properties on oral bioavailability of drugs Int J Nanomedicine 2020 15 6295 310 10.2147/ijn.s257269 32943863 PMC7455773 · DOI
  47. [47]Mu Q Jiang G Chen L Zhou H Fourches D Tropsha A Chemical basis of interactions between engineered nanoparticles and biological systems Chem Rev 2014 114 7740 81 10.1021/cr400295a 24927254 PMC4578874 · DOI
  48. [48]Nam J Won N Bang J Jin H Park J Jung S Surface engineering of inorganic nanoparticles for imaging and therapy Adv Drug Deliv Rev 2013 65 622 48 10.1016/j.addr.2012.08.015 22975010 · DOI
  49. [49]Mosleh-Shirazi S Abbasi M Shafiee M Kasaee SR Amani AM Renal clearable nanoparticles: an expanding horizon for improving biomedical imaging and cancer therapy Mater Today Commun 2021 26 102064 10.1016/j.mtcomm.2021.102064 · DOI
  50. [50]Jensen SA Day ES Ko CH Hurley LA Luciano JP Kouri FM Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma Sci Transl Med 2013 5 209ra152 10.1126/scitranslmed.3006839 PMC4017940 24174328 · DOI · Paper page
  51. [51]Yameen B Choi WI Vilos C Swami A Shi J Farokhzad OC Insight into nanoparticle cellular uptake and intracellular targeting J Control Release 2014 190 485 99 10.1016/j.jconrel.2014.06.038 24984011 PMC4153400 · DOI
  52. [52]Yabo YA Niclou SP Golebiewska A Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma Neuro Oncol 2022 24 669 82 10.1093/neuonc/noab269 34932099 PMC9071273 · DOI
  53. [53]Carter B Zhao K The epigenetic basis of cellular heterogeneity Nat Rev Genet 2021 22 235 50 10.1038/s41576-020-00300-0 33244170 PMC10880028 · DOI
  54. [54]Ramón YCS Sesé M Capdevila C Aasen T De Mattos-Arruda L Diaz-Cano SJ Clinical implications of intratumor heterogeneity: challenges and opportunities J Mol Med (Berl) 2020 98 161 77 10.1007/s00109-020-01874-2 31970428 PMC7007907 · DOI
  55. [55]Tripathi D, Shukla V, Sahoo J, Sharma DK, Shukla T. Engineered tissue in cancer research: techniques, challenges, and current status. In: Malviya R, Sundram S, eds. Targeted Cancer Therapy in Biomedical Engineering. Singapore: Springer; 2023. p. 291-324. 10.1007/978-981-19-9786-0_8. · DOI
  56. [56]Zeng Q Mousa M Nadukkandy AS Franssens L Alnaqbi H Alshamsi FY Understanding tumour endothelial cell heterogeneity and function from single-cell omics Nat Rev Cancer 2023 23 544 64 10.1038/s41568-023-00591-5 37349410 · DOI
  57. [57]Proietto M Crippa M Damiani C Pasquale V Sacco E Vanoni M Tumor heterogeneity: preclinical models, emerging technologies, and future applications Front Oncol 2023 13 1164535 10.3389/fonc.2023.1164535 37188201 PMC10175698 · DOI
  58. [58]Salemme V Centonze G Avalle L Natalini D Piccolantonio A Arina P The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity Front Oncol 2023 13 1170264 10.3389/fonc.2023.1170264 37265795 PMC10229846 · DOI
  59. [59]Sanità G Carrese B Lamberti A Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization Front Mol Biosci 2020 7 587012 10.3389/fmolb.2020.587012 33324678 PMC7726445 · DOI
  60. [60]Luo R Neu B Venkatraman SS Surface functionalization of nanoparticles to control cell interactions and drug release Small 2012 8 2585 94 10.1002/smll.201200398 22674655 · DOI
  61. [61]Romano M González Gómez MA Santonicola P Aloi N Offer S Pantzke J Synthesis and characterization of a biocompatible nanoplatform based on silica-embedded SPIONs functionalized with polydopamine ACS Biomater Sci Eng 2023 9 303 17 10.1021/acsbiomaterials.2c00946 36490313 · DOI
  62. [62]Storjohann R Gericke B Reifenrath J Herrmann T Behrens P Oltmanns H Influence of PEG chain length of functionalized magnetic nanoparticles on the cytocompatibility and immune competence of primary murine macrophages and dendritic cells Int J Mol Sci 2023 24 2565 10.3390/ijms24032565 36768890 PMC9916475 · DOI
  63. [63]Chen JL Pan CK Lin YL Tsai CY Huang YS Yang WC Preclinical evaluation of PEGylated liposomal doxorubicin as an effective radiosensitizer in chemoradiotherapy for lung cancer Strahlenther Onkol 2021 197 1131 42 10.1007/s00066-021-01835-9 34476531 · DOI
  64. [64]Vandghanooni S Eskandani M Barar J Omidi Y Aptamedicine: a new treatment modality in personalized cancer therapy Bioimpacts 2019 9 67 70 10.15171/bi.2019.09 31334037 PMC6637218 · DOI
  65. [65]Lee CK Atibalentja DF Yao LE Park J Kuruvilla S Felsher DW Anti-PD-L1 F(ab) conjugated PEG-PLGA nanoparticle enhances immune checkpoint therapy Nanotheranostics 2022 6 243 55 10.7150/ntno.65544 35145835 PMC8824669 · DOI
  66. [66]Díez-Pascual AM Surface engineering of nanomaterials with polymers, biomolecules, and small ligands for nanomedicine Materials (Basel) 2022 15 3251 10.3390/ma15093251 35591584 PMC9104878 · DOI
  67. [67]Tian L Xu B Teng KY Song M Zhu Z Chen Y Targeting Fc receptor-mediated effects and the "Don't Eat Me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer Clin Cancer Res 2022 28 201 14 10.1158/1078-0432.ccr-21-1248 34645647 PMC8963132 · DOI
  68. [69]Zhang K Wang ZQ Liu Z Qu T Zhang Z Zeng F A self-disguised nanospy for improving drug delivery efficiency via decreasing drug protonation Small 2023 19 e2300060 10.1002/smll.202300060 36929045 · DOI
  69. [70]Kaltbeitzel J Wich PR Protein‐basierte Nanopartikel: Von Wirkstofftransport zu Bildgebung, Nanokatalyse und Proteintherapie Angew Chem Int Ed Engl 2023 135 e202216097 10.1002/ange.202216097 · DOI
  70. [71]Tang Y Wang X Li J Nie Y Liao G Yu Y Overcoming the reticuloendothelial system barrier to drug delivery with a "don't-eat-us" strategy ACS Nano 2019 13 13015 26 10.1021/acsnano.9b05679 31689086 · DOI
  71. [72]Marques AC Costa PC Velho S Amaral MH Lipid nanoparticles functionalized with antibodies for anticancer drug therapy Pharmaceutics 2023 15 216 10.3390/pharmaceutics15010216 36678845 PMC9864942 · DOI
  72. [73]Pan Q Lu Y Xie L Wu D Liu R Gao W Recent advances in boosting EGFR tyrosine kinase inhibitors-based cancer therapy Mol Pharm 2023 20 829 52 10.1021/acs.molpharmaceut.2c00792 36588471 · DOI
  73. [74]Boinapally S Ahn HH Cheng B Brummet M Nam H Gabrielson KL A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile Sci Rep 2021 11 7114 10.1038/s41598-021-86551-1 33782486 PMC8007718 · DOI
  74. [75]Gessner I Neundorf I Nanoparticles modified with cell-penetrating peptides: conjugation mechanisms, physicochemical properties, and application in cancer diagnosis and therapy Int J Mol Sci 2020 21 2536 10.3390/ijms21072536 32268473 PMC7177461 · DOI · Paper page
  75. [76]Jain M Sharma GC Singh A A theoretical approach for activation of a pro-drug by its conjugate and its localization in cancer chemotherapy Math Comput Model 2009 50 333 43 10.1016/j.mcm.2009.02.014 · DOI
  76. [77]Li J Zhang Z Zhang B Yan X Fan K Transferrin receptor 1 targeted nanomedicine for brain tumor therapy Biomater Sci 2023 11 3394 413 10.1039/d2bm02152h 36847174 · DOI
  77. [78]Santhosh S, Jyothish Kumar JS, Vijayamma R. Ferritin nanocages for targeted drug delivery applications. In: Vijayamma R, Kalarikkal N, Thomas S, eds. Nanostructured Materials for Biomedical Applications. Elsevier; 2024. p. 405-33. 10.1016/b978-0-323-90838-2.00002-3. · DOI
  78. [79]Mohanty A Park IK Protein-caged nanoparticles: a promising nanomedicine against cancer Chonnam Med J 2023 59 1 12 10.4068/cmj.2023.59.1.1 36794248 PMC9900222 · DOI
  79. [80]Kesharwani P Chandra J Karim S Gupta G Karwasra R Sharma A αvβ3 integrin targeting RGD peptide-based nanoparticles as an effective strategy for selective drug delivery to tumor microenvironment J Drug Deliv Sci Technol 2024 96 105663 10.1016/j.jddst.2024.105663 · DOI
  80. [81]Pacheco C Baião A Ding T Cui W Sarmento B Recent advances in long-acting drug delivery systems for anticancer drug Adv Drug Deliv Rev 2023 194 114724 10.1016/j.addr.2023.114724 36746307 · DOI
  81. [82]Ulucan-Karnak F, Kuru Cİ. Advantages of nanodrug targeting than conventional dosage system. In: Singh RP, Singh KR, Singh J, Adetunji CO, eds. Nanotechnology for Drug Delivery and Pharmaceuticals. Academic Press; 2023. p. 295-310. 10.1016/b978-0-323-95325-2.00003-1. · DOI
  82. [83]Shen Q Du Y A comprehensive review of advanced drug delivery systems for the treatment of rheumatoid arthritis Int J Pharm 2023 635 122698 10.1016/j.ijpharm.2023.122698 36754181 · DOI
  83. [84]Sun X Zhao P Lin J Chen K Shen J Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system Cancer Drug Resist 2023 6 390 415 10.20517/cdr.2023.16 37457134 PMC10344729 · DOI
  84. [85]Bhattacharya S Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs): a reliable drug delivery system for the treatment of glioblastoma J Exp Nanosci 2021 16 344 67 10.1080/17458080.2021.1983172 · DOI
  85. [86]Ghosh A Maske P Patel V Dubey J Aniket K Srivastava R Theranostic applications of peptide-based nanoformulations for growth factor defective cancers Int J Biol Macromol 2024 260 129151 10.1016/j.ijbiomac.2023.129151 38181914 · DOI
  86. [87]Lu L Zhang Q Wang Z Gao L Shen J Peptide-modified nanoparticles for tumor targeting and molecular imaging Curr Med Chem 2021 28 6411 36 10.2174/0929867327666201022122131 33092502 · DOI
  87. [88]Hafeez MN Celia C Petrikaite V Challenges towards targeted drug delivery in cancer nanomedicines Processes 2021 9 1527 10.3390/pr9091527 · DOI
  88. [89]Bahrami B Hojjat-Farsangi M Mohammadi H Anvari E Ghalamfarsa G Yousefi M Nanoparticles and targeted drug delivery in cancer therapy Immunol Lett 2017 190 64 83 10.1016/j.imlet.2017.07.015 28760499 · DOI
  89. [90]Sun T Zhang YS Pang B Hyun DC Yang M Xia Y Engineered nanoparticles for drug delivery in cancer therapy Angew Chem Int Ed Engl 2014 53 12320 64 10.1002/anie.201403036 25294565 · DOI · Paper page
  90. [91]Wang T Jiang H Wan L Zhao Q Jiang T Wang B Potential application of functional porous TiO2 nanoparticles in light-controlled drug release and targeted drug delivery Acta Biomater 2015 13 354 63 10.1016/j.actbio.2014.11.010 25462846 · DOI
  91. [92]Murjani BO Kadu PS Bansod M Vaidya SS Yadav MD Carbon nanotubes in biomedical applications: current status, promises, and challenges Carbon Lett 2022 32 1207 26 10.1007/s42823-022-00364-4 PMC9252568 40477687 · DOI
  92. [93]Debnath SK Srivastava R Drug delivery with carbon-based nanomaterials as versatile nanocarriers: progress and prospects Front Nanotechnol 2021 3 644564 10.3389/fnano.2021.644564 · DOI
  93. [94]Selvakumar S Rajendiran T Biswas K Current advances on biomedical applications and toxicity of MWCNTs: a review BioNanoScience 2023 13 860 78 10.1007/s12668-023-01110-4 · DOI
  94. [95]Fan Z Hu X Gao RX Indirect measurement methods for quality and process control in nanomanufacturing Nanomanuf Metrol 2022 5 209 29 10.1007/s41871-022-00148-4 · DOI
  95. [96]Chen Q Riviere JE Lin Z Toxicokinetics, dose-response, and risk assessment of nanomaterials: methodology, challenges, and future perspectives Wiley Interdiscip Rev Nanomed Nanobiotechnol 2022 14 e1808 10.1002/wnan.1808 36416026 PMC9699155 · DOI
  96. [97]Ioannidis JP Kim BY Trounson A How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation Nat Biomed Eng 2018 2 797 809 10.1038/s41551-018-0314-y 30931172 PMC6436641 · DOI · Paper page
  97. [98]Tinkle SS Maximizing safe design of engineered nanomaterials: the NIH and NIEHS research perspective Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010 2 88 98 10.1002/wnan.63 20049833 · DOI
  98. [99]Aungkavattana P Indaraprasirt R Papan J Thongkam W Karlaganis G The nanosafety and ethics strategic plan of Thailand in the context of the strategic approach to international chemicals management Toxicol Environ Chem 2021 103 438 65 10.1080/02772248.2022.2045990 · DOI
  99. [100]Anuje M, Sivan A, Khot VM, Pawaskar PN. Cellular interaction and toxicity of nanostructures. In: Thorat ND, Bauer J, eds. Nanomedicines for Breast Cancer Theranostics. Elsevier; 2020. p. 193-243. 10.1016/b978-0-12-820016-2.00010-0. · DOI
  100. [101]Vandghanooni S Eskandani M Comet assay: a method to evaluate genotoxicity of nano-drug delivery system Bioimpacts 2011 1 87 97 10.5681/bi.2011.012 23678412 PMC3648950 · DOI
  101. [102]Neha D Momin M Khan T Gharat S Ningthoujam RS Omri A Metallic nanoparticles as drug delivery system for the treatment of cancer Expert Opin Drug Deliv 2021 18 1261 90 10.1080/17425247.2021.1912008 33793359 · DOI
  102. [103]Fadeel B, Pietroiusti A, Shvedova AA. Adverse Effects of Engineered Nanomaterials: Exposure, Toxicology, and Impact on Human Health. Academic Press; 2017.
  103. [104]Amorim MJB Peijnenburg W Greco D Saarimäki LA Dumit VI Bahl A Systems toxicology to advance human and environmental hazard assessment: a roadmap for advanced materials Nano Today 2023 48 101735 10.1016/j.nantod.2022.101735 · DOI
  104. [105]Wiśniewska P Haponiuk J Saeb MR Rabiee N Bencherif SA Mitigating metal-organic framework (MOF) toxicity for biomedical applications Chem Eng J 2023 471 144400 10.1016/j.cej.2023.144400 39280062 PMC11394873 · DOI
  105. [106]Magurany KA Chang X Clewell R Coecke S Haugabrooks E Marty S A pragmatic framework for the application of new approach methodologies in one health toxicological risk assessment Toxicol Sci 2023 192 155 77 10.1093/toxsci/kfad012 36782355 PMC10109535 · DOI
  106. [107]Turck D Bohn T Castenmiller J de Henauw S Hirsch-Ernst KI Knutsen HK Scientific opinion on the tolerable upper intake level for selenium EFSA J 2023 21 e07704 10.2903/j.efsa.2023.7704 36698500 PMC9854220 · DOI
  107. [108]Luty-Błocho M, Hoyos MV, Hessel V. Implications of the use of functional nanomaterials for the environment and health: risk assessment and challenges. In: Functional Nanomaterials for Sensors. CRC Press; 2023. p. 289-319.
  108. [109]Haggag YA Abosalha AK Tambuwala MM Osman EY El-Gizawy SA Essa EA Polymeric nanoencapsulation of zaleplon into PLGA nanoparticles for enhanced pharmacokinetics and pharmacological activity Biopharm Drug Dispos 2021 42 12 23 10.1002/bdd.2255 33320969 PMC7898708 · DOI
  109. [110]Lin Z Aryal S Cheng YH Gesquiere AJ Integration of in vitro and in vivo models to predict cellular and tissue dosimetry of nanomaterials using physiologically based pharmacokinetic modeling ACS Nano 2022 16 19722 54 10.1021/acsnano.2c07312 36520546 PMC9798869 · DOI
  110. [111]Biswas S, Vaze OS, Movassaghian S, Torchilin VP. Polymeric micelles for the delivery of poorly soluble drugs. In: Douroumis D, Fahr A, eds. Drug Delivery Strategies for Poorly Water‐Soluble Drugs. Wiley; 2013. p. 411-76. 10.1002/9781118444726.ch14. · DOI
  111. [112]Islam S, Thangadurai D, Adetunji CO, Micheal OS, Nwankwo W, Kadiri O, et al. Nanostructured biomaterials for targeted drug delivery. In: Biogenic Nanomaterials. Apple Academic Press; 2022. p. 83-108.
  112. [113]Firme CP 3rd Bandaru PR Toxicity issues in the application of carbon nanotubes to biological systems Nanomedicine 2010 6 245 56 10.1016/j.nano.2009.07.003 19699321 · DOI
  113. [114]Tripathi PK, Tripathi S. Dendrimers for anticancer drug delivery. In: Chauhan A, Kulhari H, eds. Pharmaceutical Applications of Dendrimers. Elsevier; 2020. p. 131-50. 10.1016/b978-0-12-814527-2.00006-8. · DOI
  114. [115]Ferreira MP Ranjan S Correia AM Mäkilä EM Kinnunen SM Zhang H In vitro and in vivo assessment of heart-homing porous silicon nanoparticles Biomaterials 2016 94 93 104 10.1016/j.biomaterials.2016.03.046 27107168 · DOI
  115. [116]Sedighi M Mahmoudi Z Abbaszadeh S Eskandari MR Saeinasab M Sefat F Nanomedicines for hepatocellular carcinoma therapy: challenges and clinical applications Mater Today Commun 2023 34 105242 10.1016/j.mtcomm.2022.105242 · DOI
  116. [117]Ma P. Drug-Loaded Lipid Nanoparticles for Improved Cancer Treatment: Engineering, In-Vitro, and In-Vivo Evaluation [dissertation]. The University of North Carolina at Chapel Hill; 2012.
  117. [118]Ho D Wang CH Chow EK Nanodiamonds: the intersection of nanotechnology, drug development, and personalized medicine Sci Adv 2015 1 e1500439 10.1126/sciadv.1500439 26601235 PMC4643796 · DOI
  118. [119]Gopinath P, Uday Kumar S, Matai I, Bhushan B, Malwal D, Sachdev A, et al. Cancer nanotheranostics. In: Cancer Nanotheranostics. Singapore: Springer; 2015. p. 1-93. 10.1007/978-981-287-435-1_1. · DOI
  119. [120]Dilnawaz F Acharya S Sahoo SK Recent trends of nanomedicinal approaches in clinics Int J Pharm 2018 538 263 78 10.1016/j.ijpharm.2018.01.016 29339248 · DOI
  120. [121]Rommasi F Esfandiari N Liposomal nanomedicine: applications for drug delivery in cancer therapy Nanoscale Res Lett 2021 16 95 10.1186/s11671-021-03553-8 34032937 PMC8149564 · DOI
  121. [122]Jarvis MF Williams M Irreproducibility in preclinical biomedical research: perceptions, uncertainties, and knowledge gaps Trends Pharmacol Sci 2016 37 290 302 10.1016/j.tips.2015.12.001 26776451 · DOI · Paper page
  122. [123]Bhattacharjee S Brayden DJ Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients Expert Opin Drug Discov 2021 16 235 54 10.1080/17460441.2021.1826434 33108229 · DOI
  123. [124]Balaure PC Grumezescu AM Smart synthetic polymer nanocarriers for controlled and site-specific drug delivery Curr Top Med Chem 2015 15 1424 90 10.2174/1568026615666150414115852 25877097 · DOI
  124. [125]Isazadeh H Oruji F Shabani S Behroozi J Nasiri H Isazadeh A Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities Mol Biol Rep 2023 50 9529 43 10.1007/s11033-023-08749-y 37741808 · DOI
  125. [126]Meyer RA Neshat SY Green JJ Santos JL Tuesca AD Targeting strategies for mRNA delivery Mater Today Adv 2022 14 100240 10.1016/j.mtadv.2022.100240 · DOI
  126. [127]Ma J Jiang L Liu G Cell membrane-coated nanoparticles for the treatment of bacterial infection Wiley Interdiscip Rev Nanomed Nanobiotechnol 2022 14 e1825 10.1002/wnan.1825 35725897 · DOI
  127. [128]Kubiatowicz LJ Mohapatra A Krishnan N Fang RH Zhang L mRNA nanomedicine: design and recent applications Exploration (Beijing) 2022 2 20210217 10.1002/exp.20210217 36249890 PMC9539018 · DOI
  128. [129]Ebrahimi N Manavi MS Nazari A Momayezi A Faghihkhorasani F Rasool Riyadh Abdulwahid AH Nano-scale delivery systems for siRNA delivery in cancer therapy: new era of gene therapy empowered by nanotechnology Environ Res 2023 239 117263 10.1016/j.envres.2023.117263 37797672 · DOI
  129. [130]Yu G Ning Q Mo Z Tang S Intelligent polymeric micelles for multidrug co-delivery and cancer therapy Artif Cells Nanomed Biotechnol 2019 47 1476 87 10.1080/21691401.2019.1601104 31070063 · DOI
  130. [131]Ribeiro AM, Amaral C, Veiga F, Figueiras A. Polymeric micelles as a versatile tool in oral chemotherapy. In: Grumezescu AM, ed. Design and Development of New Nanocarriers. William Andrew Publishing; 2018. p. 293-329. 10.1016/b978-0-12-813627-0.00008-9. · DOI
  131. [132]Varela-Moreira A Shi Y Fens MH Lammers T Hennink WE Schiffelers RM Clinical application of polymeric micelles for the treatment of cancer Mater Chem Front 2017 1 1485 501 10.1039/c6qm00289g · DOI
  132. [133]Stefani S Sharma SK Haag R Servin P Core-shell nanocarriers based on PEGylated hydrophobic hyperbranched polyesters Eur Polym J 2016 80 158 68 10.1016/j.eurpolymj.2016.05.005 · DOI
  133. [134]Shin HC Alani AW Cho H Bae Y Kolesar JM Kwon GS A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs Mol Pharm 2011 8 1257 65 10.1021/mp2000549 21630670 PMC4896148 · DOI · Paper page
  134. [135]Das BC Chokkalingam P Masilamani P Shukla S Das S Stimuli-responsive boron-based materials in drug delivery Int J Mol Sci 2023 24 2757 10.3390/ijms24032757 36769081 PMC9917063 · DOI
  135. [136]Fu S Rempson CM Puche V Zhao B Zhang F Construction of disulfide containing redox-responsive polymeric nanomedicine Methods 2022 199 67 79 10.1016/j.ymeth.2021.12.011 34971759 · DOI
  136. [137]Nguyen TT Pham KY Yook S Engineered therapeutic proteins for sustained-release drug delivery systems Acta Biomater 2023 171 131 54 10.1016/j.actbio.2023.09.018 37717712 · DOI
  137. [138]Wu SY Wu FG Chen X Antibody-incorporated nanomedicines for cancer therapy Adv Mater 2022 34 e2109210 10.1002/adma.202109210 35142395 · DOI
  138. [139]Bellavita R Braccia S Falanga A Galdiero S An overview of supramolecular platforms boosting drug delivery Bioinorg Chem Appl 2023 2023 8608428 10.1155/2023/8608428 38028018 PMC10661875 · DOI
  139. [140]Zocchi MR Tosetti F Benelli R Poggi A Cancer nanomedicine special issue review anticancer drug delivery with nanoparticles: extracellular vesicles or synthetic nanobeads as therapeutic tools for conventional treatment or immunotherapy Cancers (Basel) 2020 12 1886 10.3390/cancers12071886 32668783 PMC7409190 · DOI
  140. [141]Tripathi D Yadav P Mishra G Rai AK Experimental investigation on efficacy of Eudragit RS100 polymer in prolonging glibenclamide release by intragastric floating microsphere formulation and physicochemical evaluation Micro and Nanosystems 2024 16 123 38 10.2174/0118764029286890240314060427 · DOI
  141. [142]Cheng X Shi S Wu Y Zhu L Xu J Hu T Cisplatin-cross-linked and oxygen-resupply hyaluronic acid-based nanocarriers for chemo-photodynamic therapy ACS Appl Nano Mater 2021 4 10194 208 10.1021/acsanm.1c01662 · DOI
  142. [143]Guan Y Wang LY Wang B Ding MH Bao YL Tan SW Recent advances of D-α-tocopherol polyethylene glycol 1000 succinate-based stimuli-responsive nanomedicine for cancer treatment Curr Med Sci 2020 40 218 31 10.1007/s11596-020-2185-1 32337683 · DOI
  143. [144]Ahmad MZ Rizwanullah M Ahmad J Alasmary MY Akhter MH Abdel-Wahab BA Progress in nanomedicine-based drug delivery in designing of chitosan nanoparticles for cancer therapy Int J Polym Mater Polym Biomater 2022 71 602 23 10.1080/00914037.2020.1869737 · DOI
  144. [145]Arosio D Casagrande C Manzoni L Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles Curr Med Chem 2012 19 3128 51 10.2174/092986712800784748 22612699 · DOI
  145. [146]Zhang J Li Y Guo S Zhang W Fang B Wang S Moving beyond traditional therapies: the role of nanomedicines in lung cancer Front Pharmacol 2024 15 1363346 10.3389/fphar.2024.1363346 38389925 PMC10883231 · DOI
  146. [147]Liu H Su YY Jiang XC Gao JQ Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system Drug Deliv Transl Res 2023 13 716 37 10.1007/s13346-022-01252-0 36417162 PMC9684886 · DOI · Paper page
  147. [148]Bouyssou I Martínez FJ Campagne P Ma L Doderer-Lang C Chitnis CE Plasmodium vivax blood stage invasion pathways: contribution of omics technologies in deciphering molecular and cellular mechanisms C R Biol 2022 345 91 133 10.5802/crbiol.95 36847467 · DOI
  148. [149]Bajracharya R Song JG Patil BR Lee SH Noh HM Kim DH Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems Drug Deliv 2022 29 1959 70 10.1080/10717544.2022.2089296 35762636 PMC9246174 · DOI
  149. [150]Bera S Mondal D Antibacterial efficacies of nanostructured aminoglycosides ACS Omega 2022 7 4724 34 10.1021/acsomega.1c04399 35187293 PMC8851436 · DOI
  150. [151]Zhang W Zhao M Gao Y Cheng X Liu X Tang S Biomimetic erythrocytes engineered drug delivery for cancer therapy Chem Eng J 2022 433 133498 10.1016/j.cej.2021.133498 · DOI
  151. [152]Chellappan DK Prasher P Saravanan V Vern Yee VS Wen Chi WC Wong JW Protein and peptide delivery to lungs by using advanced targeted drug delivery Chem Biol Interact 2022 351 109706 10.1016/j.cbi.2021.109706 34662570 · DOI
  152. [153]Beh CY Prajnamitra RP Chen LL Hsieh PC Advances in biomimetic nanoparticles for targeted cancer therapy and diagnosis Molecules 2021 26 5052 10.3390/molecules26165052 34443638 PMC8401254 · DOI
  153. [154]Li X Naeem A Xiao S Hu L Zhang J Zheng Q Safety challenges and application strategies for the use of dendrimers in medicine Pharmaceutics 2022 14 1292 10.3390/pharmaceutics14061292 35745863 PMC9230513 · DOI
  154. [155]Bober Z Bartusik-Aebisher D Aebisher D Application of dendrimers in anticancer diagnostics and therapy Molecules 2022 27 3237 10.3390/molecules27103237 35630713 PMC9144149 · DOI
  155. [157]Mignani S Rodrigues J Roy R Shi X Ceña V El Kazzouli S Exploration of biomedical dendrimer space based on in-vivo physicochemical parameters: key factor analysis (part 2) Drug Discov Today 2019 24 1184 92 10.1016/j.drudis.2019.03.001 30904723 · DOI
  156. [158]Chavan T, Muttil P, Kunda NK. Introduction to nanomedicine in drug delivery. In: Muttil P, Kunda NK, eds. Mucosal Delivery of Drugs and Biologics in Nanoparticles. Cham: Springer; 2020. p. 3-26. 10.1007/978-3-030-35910-2_1. · DOI
  157. [159]Swami R Singh I Jeengar MK Naidu VG Khan W Sistla R Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting Int J Pharm 2015 486 287 96 10.1016/j.ijpharm.2015.03.065 25839415 · DOI
  158. [160]Sun J Bi C Chan HM Sun S Zhang Q Zheng Y Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability Colloids Surf B Biointerfaces 2013 111 367 75 10.1016/j.colsurfb.2013.06.032 23856543 · DOI
  159. [161]Andrade LM Costa GM Insights into gold nanoparticles possibilities for diagnosis and treatment of the head and neck upper aerodigestive tract cancers Cancers (Basel) 2023 15 2080 10.3390/cancers15072080 37046740 PMC10093449 · DOI
  160. [162]Saleh E Ukwas A Adenoid cystic carcinoma of salivary glands: a ten-year review and an assessment of the current management, surgery, radiotherapy, and chemotherapy Int J Otolaryngol 2023 2023 7401458 10.1155/2023/7401458 37159817 PMC10163974 · DOI
  161. [163]Oner E, Ilhan M, Gultekin HE, Karpuz M. Nanoconjugate formulations for enhanced drug delivery. In: Nayak AK, Hasnain MS, Laha B, Maiti S, eds. Advanced and Modern Approaches for Drug Delivery. Academic Press; 2023. p. 441-91. 10.1016/b978-0-323-91668-4.00023-x. · DOI · Paper page
  162. [164]da Silva FJ Carvalho de Azevedo J Jr Ralph AC de Jesus Viana Pinheiro J Freitas VM Calcagno DQ Salivary glands adenoid cystic carcinoma: a molecular profile update and potential implications Front Oncol 2023 13 1191218 10.3389/fonc.2023.1191218 37476370 PMC10354556 · DOI
  163. [165]Zhang A Gao L The refined application and evolution of nanotechnology in enhancing radiosensitivity during radiotherapy: transitioning from gold nanoparticles to multifunctional nanomaterials Int J Nanomedicine 2023 18 6233 56 10.2147/ijn.s436268 37936951 PMC10626338 · DOI
  164. [166]Cruz-Hernández CD Rodríguez-Martínez G Cortés-Ramírez SA Morales-Pacheco M Cruz-Burgos M Losada-García A Aptamers as theragnostic tools in prostate cancer Biomolecules 2022 12 1056 10.3390/biom12081056 36008950 PMC9406110 · DOI
  165. [167]Mueller SK Haderlein M Lettmaier S Agaimy A Haller F Hecht M Targeted therapy, chemotherapy, immunotherapy and novel treatment options for different subtypes of salivary gland cancer J Clin Med 2022 11 720 10.3390/jcm11030720 35160172 PMC8836387 · DOI
  166. [168]Fathi-Karkan S Arshad R Rahdar A Ramezani A Behzadmehr R Ghotekar S Recent advancements in the targeted delivery of etoposide nanomedicine for cancer therapy: a comprehensive review Eur J Med Chem 2023 259 115676 10.1016/j.ejmech.2023.115676 37499287 · DOI
  167. [169]Wang S He H Mao Y Zhang Y Gu N Advances in atherosclerosis theranostics harnessing iron oxide‐based nanoparticles Adv Sci 2024 11 2308298 10.1002/advs.202308298 PMC11077671 38368274 · DOI
  168. [170]de Maglie M. Biodistribution and Toxicity of Metallic Nanoparticles: In Vivo Studies in Mice [dissertation] Università degli Studi di Milano; 2017.
  169. [171]Sanmartín-Matalobos J Bermejo-Barrera P Aboal-Somoza M Fondo M García-Deibe AM Corredoira-Vázquez J Semiconductor quantum dots as target analytes: properties, surface chemistry and detection Nanomaterials (Basel) 2022 12 2501 10.3390/nano12142501 35889725 PMC9318497 · DOI
  170. [172]Saadh MJ Abdulsahib WK Mustafa AN Zabibah RS Adhab ZH Rakhimov N Recent advances in natural nanoclay for diagnosis and therapy of cancer: a review Colloids Surf B Biointerfaces 2024 235 113768 10.1016/j.colsurfb.2024.113768 38325142 · DOI
  171. [173]He C Zhang S Liu X Wang J Huang Y Zhang A CaO2 nanomedicines: a review of their emerging roles in cancer therapy Nanotechnology 2023 34 482002 10.1088/1361-6528/acf381 37619542 · DOI
  172. [174]Fu Z Fan K He X Wang Q Yuan J Lim KS Single-atom-based nanoenzyme in tissue repair ACS Nano 2024 18 12639 71 10.1021/acsnano.4c00308 38718193 · DOI
  173. [175]Wang S Chen Y Guo J Huang Q Liposomes for tumor targeted therapy: a review Int J Mol Sci 2023 24 2643 10.3390/ijms24032643 36768966 PMC9916501 · DOI
  174. [176]Ci T Zhang W Qiao Y Li H Zang J Li H Delivery strategies in treatments of leukemia Chem Soc Rev 2022 51 2121 44 10.1039/d1cs00755f 35188506 · DOI
  175. [177]Nikolova MP Kumar EM Chavali MS Updates on responsive drug delivery based on liposome vehicles for cancer treatment Pharmaceutics 2022 14 2195 10.3390/pharmaceutics14102195 36297630 PMC9608678 · DOI
  176. [178]Taher M Susanti D Haris MS Rushdan AA Widodo RT Syukri Y PEGylated liposomes enhance the effect of cytotoxic drug: a review Heliyon 2023 9 e13823 10.1016/j.heliyon.2023.e13823 36873538 PMC9976326 · DOI
  177. [179]Pandey P Arya DK Deepak P Ali D Alarifi S Srivastava S αvβ3 integrin and folate-targeted pH-sensitive liposomes with dual ligand modification for metastatic breast cancer treatment Bioengineering (Basel) 2024 11 800 10.3390/bioengineering11080800 39199757 PMC11352135 · DOI
  178. [180]Gonçalves M Mignani S Rodrigues J Tomás H A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market J Control Release 2020 317 347 74 10.1016/j.jconrel.2019.11.016 31751636 · DOI
  179. [181]Liu Y Hong G Mao L Su Z Liu T Liu H A novel paclitaxel derivative for triple-negative breast cancer chemotherapy Molecules 2023 28 3662 10.3390/molecules28093662 37175072 PMC10180349 · DOI
  180. [182]Jian J He D Gao S Tao X Dong X Pharmacokinetics in pharmacometabolomics: towards personalized medication Pharmaceuticals (Basel) 2023 16 1568 10.3390/ph16111568 38004434 PMC10675232 · DOI
  181. [183]Lilienthal I Herold N Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies Int J Mol Sci 2020 21 6885 10.3390/ijms21186885 32961800 PMC7555161 · DOI
  182. [184]Mohajeri M Behnam B Sahebkar A Biomedical applications of carbon nanomaterials: drug and gene delivery potentials J Cell Physiol 2018 234 298 319 10.1002/jcp.26899 30078182 · DOI
  183. [185]Rahamathulla M Bhosale RR Osmani RA Mahima KC Johnson AP Hani U Carbon nanotubes: current perspectives on diverse applications in targeted drug delivery and therapies Materials (Basel) 2021 14 6707 10.3390/ma14216707 34772234 PMC8588285 · DOI
  184. [186]Contreras-Torres FF Salas-Treviño D Soto-Domínguez A de Jesús García-Rivas G Carbon nanotubes in tumor-targeted chemotherapeutic formulations: a review of opportunities and challenges ACS Appl Nano Mater 2022 5 8649 79 10.1021/acsanm.2c01118 · DOI
  185. [187]Jha R Singh A Sharma PK Fuloria NK Smart carbon nanotubes for drug delivery system: a comprehensive study J Drug Deliv Sci Technol 2020 58 101811 10.1016/j.jddst.2020.101811 · DOI
  186. [188]Prajapati SK Malaiya A Kesharwani P Soni D Jain A Biomedical applications and toxicities of carbon nanotubes Drug Chem Toxicol 2022 45 435 50 10.1080/01480545.2019.1709492 31908176 · DOI
  187. [189]Hosseini SM Mohammadnejad J Najafi-Taher R Beiram Zadeh Z Tanhaei M Ramakrishna S Multifunctional carbon-based nanoparticles: theranostic applications in cancer therapy and diagnosis ACS Appl Bio Mater 2023 6 1323 38 10.1021/acsabm.2c01000 36921253 · DOI
  188. [190]Francis AP Devasena T Toxicity of carbon nanotubes: a review Toxicol Ind Health 2018 34 200 10 10.1177/0748233717747472 29506458 · DOI
  189. [191]Ahmadian E Janas D Eftekhari A Zare N Application of carbon nanotubes in sensing/monitoring of pancreas and liver cancer Chemosphere 2022 302 134826 10.1016/j.chemosphere.2022.134826 35525455 · DOI
  190. [192]Madani SY Tan A Naderi N Seifalian AM Application of OctaAmmonium-POSS functionalized single walled carbon nanotubes for thermal treatment of cancer J Nanosci Nanotechnol 2012 12 9018 28 10.1166/jnn.2012.6746 23447953 · DOI
  191. [193]Attama AA Nnamani PO Onokala OB Ugwu AA Onugwu AL Nanogels as target drug delivery systems in cancer therapy: a review of the last decade Front Pharmacol 2022 13 874510 10.3389/fphar.2022.874510 36160424 PMC9493206 · DOI
  192. [194]Seth A, Sharma PA, Maheshwari R, Tekade M, Shrivastava SK, Tekade RK. Dendrimers in targeted drug delivery. In: Dendrimers for Drug Delivery. Apple Academic Press; 2018. p. 225-66.
  193. [195]Ahamed MN, Ragul V. Toxicity Towards Nanostructured Biomaterials in Human Health. In: Nanobiomaterials. CRC Press; 2023. p. 58-70.
  194. [196]Hoy SM Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer Drugs 2014 74 1757 68 10.1007/s40265-014-0291-8 25260887 · DOI
  195. [197]Blair HA Deeks ED Albumin-bound paclitaxel: a review in non-small cell lung cancer Drugs 2015 75 2017 24 10.1007/s40265-015-0484-9 26541764 · DOI
  196. [198]Samal SK Cancer and carbon nano tubes: a promising hope of future Sci Rev 2018 4 64 7 10.32861/sr.47.64.67 · DOI
  197. [199]Rhaman MM Islam MR Akash S Mim M Noor Alam M Nepovimova E Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: at a glance Front Cell Dev Biol 2022 10 989471 10.3389/fcell.2022.989471 36120565 PMC9478743 · DOI · Paper page
  198. [200]Corsi I Venditti I Trotta F Punta C Environmental safety of nanotechnologies: the eco-design of manufactured nanomaterials for environmental remediation Sci Total Environ 2023 864 161181 10.1016/j.scitotenv.2022.161181 36581299 · DOI
  199. [201]Lebre F Chatterjee N Costa S Fernández-de-Gortari E Lopes C Meneses J Nanosafety: an evolving concept to bring the safest possible nanomaterials to society and environment Nanomaterials (Basel) 2022 12 1810 10.3390/nano12111810 35683670 PMC9181910 · DOI
  200. [202]Wibowo YG Ramadan BS Taher T Khairurrijal K Advancements of nanotechnology and nanomaterials in environmental and human protection for combatting the COVID-19 during and post-pandemic era: a comprehensive scientific review Biomed Mater Devices 2024 2 34 57 10.1007/s44174-023-00086-9 PMC10171735 37363141 · DOI

200 of 208 shown

Cited by

Sorted by citations

See all 43

Metadata

Authors
Tripathi, D., Pandey, P., Sharma, S., Rai, A. K., & Prabhu B.H., M.
Venue
BioImpacts
Publisher
Maad Rayan Publishing Company
Published
2024-11-02
ISSN
  • 2228-5652
  • 2228-5660
DOI
10.34172/bi.30573
PMC
PMC12008503
Cited by
43
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity. https://app.cochat.ai/papers/10.34172/bi.30573
The paper
Tripathi, D., Pandey, P., Sharma, S., Rai, A. K., & Prabhu B.H., M. (2024). Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity. BioImpacts. https://doi.org/10.34172/bi.30573